Polaryx Therapeutics, Inc. (PLYX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.89

From 52W high−94.63%

Volume27169.00

Market cap$93.71M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.89

From 52W high

−94.63%

Volume

27169.00

Market cap

$93.71M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

P/E (TTM)

—

RSI (14)

34.9

MomentumView details →

1D Return

+0.00%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−12.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

8.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−62.61%

ROA (TTM)

−57.98%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−18.75%

EBITDA YoY

+9.33%

MomentumView details →

1D Return

+0.00%

YTD Return

—

1Y Return

—

RSI (14)

34.9

vs 50D SMA

−10.18%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.53x

Quick Ratio

13.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

14.29%

Beats (12Q)

1/12

Next Q EPS Est

−$0.05

Avg Surprise (4Q)

−45.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−6.85M

Op. CF (TTM)

−5.81M

Latest newsMore news →

Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.56d ago

Polaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.145d ago

Similar companies

Insight Molecular Diagnostics Inc.IMDX Conexeu Sciences Inc.CNXU PMV Pharmaceuticals, Inc.PMVP Immunic, Inc.IMUX ImmuCell CorporationICCC Cellectis S.A.CLLS Find similar companies →

Latest newsMore news →

Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.56d ago Polaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.145d ago